Clinical Trial Update: A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 [Phase 3]

View source ↗

Summary

This is a clinical trial update describing a Phase 3 study of NLS-2, mazindol extended release, for Narcolepsy Type 1 (with cataplexy), which is currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy Type
• Narcolepsy with Cataplexy

Drugs mentioned

• NLS-2 (Mazindol Extended Release) (mazindol extended release)

Snippet

Sponsor: NLS Pharmaceutics | Conditions: Narcolepsy Type 1, Narcolepsy With Cataplexy | Phase 3 | Status: NOT_YET_RECRUITING